Shire Stock Price, News & Analysis (NASDAQ:SHPG)

$148.50 0.50 (0.34 %)
(As of 12/12/2017 03:07 AM ET)
Previous Close$148.00
Today's Range$147.55 - $149.76
52-Week Range$137.17 - $192.15
Volume629,000 shs
Average Volume1.13 million shs
Market Capitalization$44.86 billion
P/E Ratio10.18
Dividend Yield0.62%
Beta1.59

About Shire (NASDAQ:SHPG)

Shire logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SHPG
CUSIPN/A
Phone+353-1-6096000

Debt

Debt-to-Equity Ratio0.55%
Current Ratio0.98%
Quick Ratio0.52%

Price-To-Earnings

Trailing P/E Ratio10.18
Forward P/E Ratio9.90
P/E Growth0.82

Sales & Book Value

Annual Sales$11.40 billion
Price / Sales3.92
Cash Flow$16.43 per share
Price / Cash9.04
Book Value$95.20 per share
Price / Book1.56

Profitability

Trailing EPS$5.31
Net Income$327.40 million
Net Margins10.95%
Return on Equity14.41%
Return on Assets6.60%

Miscellaneous

Employees23,906
Outstanding Shares300,740,000

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a semiannual dividend on Friday, August 11th. Stockholders of record on Friday, September 8th will be given a dividend of $0.1527 per share on Friday, October 20th. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) released its earnings results on Friday, October, 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping analysts' consensus estimates of $3.64 by $0.17. The biopharmaceutical company had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company's quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the company posted $3.17 EPS. View Shire's Earnings History.

When will Shire make its next earnings announcement?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, February, 15th 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire issued an update on its FY17 earnings guidance on Friday, October, 27th. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.92. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $14.97 billion.

Where is Shire's stock going? Where will Shire's stock price be in 2017?

14 brokers have issued twelve-month price targets for Shire's stock. Their predictions range from $160.00 to $245.00. On average, they anticipate Shire's share price to reach $212.18 in the next year. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:

  • 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have risen ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters." (10/27/2017)
  • 2. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
  • 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Are investors shorting Shire?

Shire saw a increase in short interest in November. As of November 30th, there was short interest totalling 3,854,721 shares, an increase of 38.7% from the November 15th total of 2,779,249 shares. Based on an average daily trading volume, of 1,385,919 shares, the days-to-cover ratio is presently 2.8 days.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
  • Joanne Cordeiro, Chief Human Resource Officer
  • Howard Mayer M.D., Chief Medical Officer
  • Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
  • William Mordan, General Counsel, Company Secretary (Age 47)
  • Perry Sternberg, Head - U.S. Commercial (Age 48)
  • Kim Stratton, Head - International Commercial (Age 54)
  • Philip J. Vickers, Head - Research and Development (Age 56)
  • Matthew Walker, Head - Technical Operations (Age 53)
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board (Age 58)

Who owns Shire stock?

Shire's stock is owned by many different of institutional and retail investors. Top institutional investors include Harding Loevner LP (42.47%), Janus Henderson Group PLC (0.58%), Ameriprise Financial Inc. (0.53%), Boston Partners (0.49%), Third Point LLC (0.40%) and Jennison Associates LLC (0.26%). View Institutional Ownership Trends for Shire.

Who sold Shire stock? Who is selling Shire stock?

Shire's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Allianz Asset Management GmbH, Sei Investments Co., Dividend Assets Capital LLC, Rockefeller Financial Services Inc., Third Avenue Management LLC, Zweig DiMenna Associates LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for Shire.

Who bought Shire stock? Who is buying Shire stock?

Shire's stock was acquired by a variety of institutional investors in the last quarter, including Harding Loevner LP, Third Point LLC, Sterling Capital Management LLC, Janus Henderson Group PLC, Seatown Holdings Pte. Ltd., Van ECK Associates Corp, Boston Partners and GMT Capital Corp. View Insider Buying and Selling for Shire.

How do I buy Shire stock?

Shares of Shire can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of Shire stock can currently be purchased for approximately $148.50.

How big of a company is Shire?

Shire has a market capitalization of $44.86 billion and generates $11.40 billion in revenue each year. The biopharmaceutical company earns $327.40 million in net income (profit) each year or $5.31 on an earnings per share basis. Shire employs 23,906 workers across the globe.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  832 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  1,201
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.762.742.742.84
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $211.00$213.15$222.42$221.49
Price Target Upside: 45.18% upside49.93% upside52.81% upside34.22% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
11/16/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/14/2017Liberum CapitalUpgradeHold -> BuyN/AView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/29/2017CowenSet Price TargetBuy$225.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$160.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
4/17/2017Goldman Sachs GroupBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna BancsharesLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018        
10/27/20179/30/2017$3.64$3.81$3.70 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Shire (NASDAQ:SHPG) Earnings Estimates

2017 EPS Consensus Estimate: $14.66
2018 EPS Consensus Estimate: $16.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.61
Q3 20175$3.59$3.89$3.74
Q4 20175$3.72$4.26$3.99
Q1 20182$3.97$4.01$3.99
Q2 20182$3.97$4.13$4.05
Q3 20182$4.07$4.08$4.08
Q4 20182$4.37$4.43$4.40
(Data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Most Recent Dividend:10/20/2017
Annual Dividend:$0.92
Dividend Yield:0.62%
Payout Ratio:17.33% (Trailing 12 Months of Earnings)
6.13% (Based on This Year's Estimates)
5.75% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/11/2017semiannual$0.150.21%9/7/20179/8/201710/20/2017
2/24/2017$0.773/8/20173/10/20174/25/2017
8/5/2016$0.149/7/20169/9/201610/7/2016
2/11/2016$0.673/9/20163/11/20164/12/2016
7/23/2015$0.139/2/20159/4/201510/2/2015
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire (NASDAQ SHPG)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
Shire (SHPG) a Sell on Sagging Quant ScoreShire (SHPG) a Sell on Sagging Quant Score
investorplace.com - December 11 at 3:49 PM
Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill TechnologyWired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology
finance.yahoo.com - December 7 at 10:17 AM
Critical Survey: Shire (SHPG) versus Warner Chilcott (WCRX)Critical Survey: Shire (SHPG) versus Warner Chilcott (WCRX)
www.americanbankingnews.com - December 6 at 7:52 AM
Shire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald AnalystsShire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 5 at 11:22 AM
Rani Therapeutics, Shire Partner To Develop Oral FVIII Delivery - Quick FactsRani Therapeutics, Shire Partner To Develop Oral FVIII Delivery - Quick Facts
www.nasdaq.com - December 5 at 10:41 AM
How Financially Strong Is Shire plc (LSE:SHP)?How Financially Strong Is Shire plc (LSE:SHP)?
finance.yahoo.com - December 5 at 10:41 AM
Shire in deal to develop a new way to administer hemophilia drugShire in deal to develop a new way to administer hemophilia drug
finance.yahoo.com - December 5 at 10:41 AM
Amphastar Pharmaceuticals (AMPH) and Shire (SHPG) Head-To-Head AnalysisAmphastar Pharmaceuticals (AMPH) and Shire (SHPG) Head-To-Head Analysis
www.americanbankingnews.com - December 5 at 5:52 AM
Lousy Quant Score Make Shire (SHPG) a SellLousy Quant Score Make Shire (SHPG) a Sell
investorplace.com - December 4 at 4:26 PM
Shire : FDA Grants Orphan Drug Designation For Anti-MAdCAM Antibody SHP647Shire : FDA Grants Orphan Drug Designation For Anti-MAdCAM Antibody SHP647
www.nasdaq.com - November 30 at 10:27 AM
U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric PatientsU.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients
feeds.benzinga.com - November 30 at 7:52 AM
Shire (SHPG) a Sell on Flopping Industry Group RankShire (SHPG) a Sell on Flopping Industry Group Rank
investorplace.com - November 27 at 3:47 PM
Shire PLC (SHPG) Receives Consensus Recommendation of "Buy" from BrokeragesShire PLC (SHPG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 26 at 1:58 PM
Shire plc : Block listing Interim ReviewShire plc : Block listing Interim Review
finance.yahoo.com - November 24 at 6:03 PM
$3.89 Earnings Per Share Expected for Shire PLC (SHPG) This Quarter$3.89 Earnings Per Share Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - November 22 at 9:34 PM
Shire plc : Directorate change - GlobeNewswire (press release)Shire plc : Directorate change - GlobeNewswire (press release)
globenewswire.com - November 20 at 9:54 AM
Ultragenyxs rhGUS Gets FDA Nod for Rare Genetic DiseaseUltragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
www.nasdaq.com - November 17 at 7:06 PM
Cantor Fitzgerald Reiterates "$222.00" Price Target for Shire PLC (SHPG)Cantor Fitzgerald Reiterates "$222.00" Price Target for Shire PLC (SHPG)
www.americanbankingnews.com - November 16 at 3:28 PM
Shire PLC (SHPG) Stock Rating Reaffirmed by Royal Bank Of CanadaShire PLC (SHPG) Stock Rating Reaffirmed by Royal Bank Of Canada
www.americanbankingnews.com - November 16 at 3:28 PM
Polygon Management Ltd. Buys Shire PLC, IAC/InterActiveCorp, Ambac Financial Group Inc, Sells ... - NasdaqPolygon Management Ltd. Buys Shire PLC, IAC/InterActiveCorp, Ambac Financial Group Inc, Sells ... - Nasdaq
www.nasdaq.com - November 15 at 3:42 PM
Shire PLC (SHPG) Lifted to Buy at Liberum CapitalShire PLC (SHPG) Lifted to Buy at Liberum Capital
www.americanbankingnews.com - November 14 at 8:28 PM
Shire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing AuthorizationShire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing Authorization
www.nasdaq.com - November 14 at 7:53 AM
European advisory group backs Shires long-acting Factor VIII for hemophilia AEuropean advisory group backs Shire's long-acting Factor VIII for hemophilia A
seekingalpha.com - November 14 at 7:53 AM
CHMP recommends EU marketing authorization for ADYNOVI®  for adults and adolescents with Hemophilia ACHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A
finance.yahoo.com - November 14 at 7:53 AM
Analytics for Industry Group Rank Make Shire (SHPG) a SellAnalytics for Industry Group Rank Make Shire (SHPG) a Sell
investorplace.com - November 13 at 4:58 PM
Dan Loeb Soars High in Alibaba - NasdaqDan Loeb Soars High in Alibaba - Nasdaq
www.nasdaq.com - November 11 at 1:34 PM
Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and OncologyShire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology
feeds.benzinga.com - November 10 at 7:56 AM
FY2019 EPS Estimates for Shire PLC (SHPG) Reduced by SunTrust BanksFY2019 EPS Estimates for Shire PLC (SHPG) Reduced by SunTrust Banks
www.americanbankingnews.com - November 9 at 3:40 PM
Shire PLC Forecasted to Post Q4 2017 Earnings of $3.80 Per Share (SHPG)Shire PLC Forecasted to Post Q4 2017 Earnings of $3.80 Per Share (SHPG)
www.americanbankingnews.com - November 8 at 1:14 PM
$4.00 Billion in Sales Expected for Shire PLC (SHPG) This Quarter$4.00 Billion in Sales Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - November 5 at 6:44 AM
ETFs with exposure to Shire Plc : November 3, 2017ETFs with exposure to Shire Plc : November 3, 2017
finance.yahoo.com - November 4 at 2:50 PM
Zacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPSZacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPS
www.americanbankingnews.com - November 3 at 7:34 PM
Head-To-Head Comparison: Shire PLC (SHPG) vs. Impax Laboratories (IPXL)Head-To-Head Comparison: Shire PLC (SHPG) vs. Impax Laboratories (IPXL)
www.americanbankingnews.com - November 2 at 5:30 PM
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plcXenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
finance.yahoo.com - November 2 at 8:45 AM
Earnings Review and Free Research Report: Eli Lilly’s Adjusted EPS Increased 19%Earnings Review and Free Research Report: Eli Lilly’s Adjusted EPS Increased 19%
finance.yahoo.com - November 2 at 8:44 AM
Shire PLC (SHPG) Given Consensus Recommendation of "Buy" by BrokeragesShire PLC (SHPG) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 3:42 PM
Q4 2017 EPS Estimates for Shire PLC Cut by William Blair (SHPG)Q4 2017 EPS Estimates for Shire PLC Cut by William Blair (SHPG)
www.americanbankingnews.com - November 1 at 11:31 AM
FY2017 EPS Estimates for Shire PLC (SHPG) Cut by Cantor FitzgeraldFY2017 EPS Estimates for Shire PLC (SHPG) Cut by Cantor Fitzgerald
www.americanbankingnews.com - November 1 at 8:54 AM
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong - NasdaqShire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong - Nasdaq
www.nasdaq.com - October 31 at 9:25 AM
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise StrongShire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
finance.yahoo.com - October 31 at 9:25 AM
Analysts Issue Forecasts for Shire PLCs FY2017 Earnings (SHPG)Analysts Issue Forecasts for Shire PLC's FY2017 Earnings (SHPG)
www.americanbankingnews.com - October 31 at 6:48 AM
Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)
www.americanbankingnews.com - October 31 at 6:48 AM
Falling Earnings Visibility Keeps Shire (SHPG) a SellFalling Earnings Visibility Keeps Shire (SHPG) a Sell
investorplace.com - October 30 at 3:59 PM
Fund manager, analysts make the case for this ‘loathed’ pharma stockFund manager, analysts make the case for this ‘loathed’ pharma stock
finance.yahoo.com - October 30 at 7:05 AM
Shire PLC (SHPG) Stock Rating Reaffirmed by Cantor FitzgeraldShire PLC (SHPG) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - October 28 at 2:08 PM
Shire PLC (SHPG) Posts  Earnings Results, Beats Estimates By $0.15 EPSShire PLC (SHPG) Posts Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - October 27 at 9:32 PM
Zacks Investment Research Upgrades Shire PLC (SHPG) to HoldZacks Investment Research Upgrades Shire PLC (SHPG) to Hold
www.americanbankingnews.com - October 27 at 1:00 PM
Shire PLC (SHPG) Releases FY17 Earnings GuidanceShire PLC (SHPG) Releases FY17 Earnings Guidance
www.americanbankingnews.com - October 27 at 8:56 AM
Shire plc : 3rd Quarter ResultsShire plc : 3rd Quarter Results
feeds.benzinga.com - October 27 at 8:05 AM
Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric PatientsShire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients
feeds.benzinga.com - October 26 at 2:51 AM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

DateFilerForm TypeView
12/08/2017
9:50 AM
Shire (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/01/2017
3:31 PM
Shire (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.